Tadashi Sakaguchi1, Kentaro Ito2, Kazuki Furuhashi3, Yuki Nakamura4, Yuta Suzuki5, Yoichi Nishii6, Osamu Taguchi7, Osamu Hataji8. 1. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan; St. Marianna University School of Medicine, Division of Respiratory Medicine, 2-16-1 Sugao, Miyamae, Kanagawa, 216-8511, Japan. Electronic address: mchsakaguchi@city-hosp.matsusaka.mie.jp. 2. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan. Electronic address: kentarou_i_0214@yahoo.co.jp. 3. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan. Electronic address: mchkazuki.f@city-hosp.matsusaka.mie.jp. 4. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan. Electronic address: mch.y-nkmr@city-hosp.matsusaka.mie.jp. 5. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan. Electronic address: mchyu-ta@city-hosp.matsusaka.mie.jp. 6. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan. Electronic address: mchnishii@city-hosp.matsusaka.mie.jp. 7. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan. Electronic address: mchosamutaguchi@city-hosp.matsusaka.mie.jp. 8. Respiratory Center, Matsusaka Municipal Hospital, 1550, Tonomachi, Matsusaka, Mie, 515-0073, Japan. Electronic address: mch1031@city-hosp.matsusaka.mie.jp.
Abstract
BACKGROUND: Compared to a placebo, durvalumab has been reported to significantly prolong progression-free and overall survival in patients with stage III unresectable non-small cell lung cancer (NSCLC) after chemoradiotherapy. The aim of this retrospective study was to evaluate the eligibility of patients with unresectable stage III NSCLC able to receive consolidation therapy with durvalumab in clinical practice based on the PACIFIC study criteria. METHODS: From January 2011 to May 2018, electronic data were collected from patients diagnosed with unresectable stage III NSCLC treated with definitive chemoradiotherapy. A total of 81 patients were identified. Of these, 73 were treated with platinum-based chemotherapy based on the PACIFIC study criteria. RESULTS: Radiation pneumonitis of any grade occurred in 54 patients (73.9%) who received definitive chemoradiotherapy. Of these, 12 (16.4%) developed radiation pneumonitis of grade 2 or more within 42 days after chemoradiotherapy and were excluded from durvalumab treatment. Two patients (2.7%) developed other pneumonitis, seven patients (9.6%) showed poor performance status, and three patients (4.1%) displayed disease progression at the initial assessment. After considering overlapping cases mentioned above, 22 patients (30.1%) were ineligible to receive durvalumab by the criteria utilized in the PACIFIC study. CONCLUSION: In clinical practice, approximately 70% of patients with unresectable stage III NSCLC would be eligible to receive consolidation therapy with durvalumab.
BACKGROUND: Compared to a placebo, durvalumab has been reported to significantly prolong progression-free and overall survival in patients with stage III unresectable non-small cell lung cancer (NSCLC) after chemoradiotherapy. The aim of this retrospective study was to evaluate the eligibility of patients with unresectable stage III NSCLC able to receive consolidation therapy with durvalumab in clinical practice based on the PACIFIC study criteria. METHODS: From January 2011 to May 2018, electronic data were collected from patients diagnosed with unresectable stage III NSCLC treated with definitive chemoradiotherapy. A total of 81 patients were identified. Of these, 73 were treated with platinum-based chemotherapy based on the PACIFIC study criteria. RESULTS: Radiation pneumonitis of any grade occurred in 54 patients (73.9%) who received definitive chemoradiotherapy. Of these, 12 (16.4%) developed radiation pneumonitis of grade 2 or more within 42 days after chemoradiotherapy and were excluded from durvalumab treatment. Two patients (2.7%) developed other pneumonitis, seven patients (9.6%) showed poor performance status, and three patients (4.1%) displayed disease progression at the initial assessment. After considering overlapping cases mentioned above, 22 patients (30.1%) were ineligible to receive durvalumab by the criteria utilized in the PACIFIC study. CONCLUSION: In clinical practice, approximately 70% of patients with unresectable stage III NSCLC would be eligible to receive consolidation therapy with durvalumab.
Authors: J Agulnik; G Kasymjanova; C Pepe; M Hurry; R N Walton; L Sakr; V Cohen; M Lecavalier; D Small Journal: Curr Oncol Date: 2020-10-01 Impact factor: 3.677
Authors: Narek Shaverdian; Michael D Offin; Andreas Rimner; Annemarie F Shepherd; Abraham J Wu; Charles M Rudin; Matthew D Hellmann; Jamie E Chaft; Daniel R Gomez Journal: Radiother Oncol Date: 2019-11-28 Impact factor: 6.280
Authors: Tanja Eichkorn; Farastuk Bozorgmehr; Sebastian Regnery; Lisa A Dinges; Andreas Kudak; Nina Bougatf; Dorothea Weber; Petros Christopoulos; Thomas Muley; Sonja Kobinger; Laila König; Juliane Hörner-Rieber; Sebastian Adeberg; Claus Peter Heussel; Michael Thomas; Jürgen Debus; Rami A El Shafie Journal: Front Oncol Date: 2020-12-01 Impact factor: 6.244